Our Technology

Leveraging on the power of exceptional "mRNA 2.0" platform, we incorporate specialized LNP delivery, mRNA synthesis, and formulation technologies to tackle challenges in the vaccine and immuno-oncology sectors.

​

Employing "Structure-based antigen design" and "AI-assisted mRNA sequence optimization"  technologies, we can generate a target antigen with optimal stability and immunogenicity while minimizing toxicity.